Solara Active Pharma Sciences growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+6.6%−1.8%
EBITDA−9.5%+11.7%
Total Assets+4.5%−7.0%
Total Equity+14.5%−5.8%
Free Cash Flow−42.1%+30.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SOLARA₹653.80

Solara Active Pharma Sciences Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABDCALSMSPHARMAHIKALPANACEABIOSAIPARENTINDOCOUNICHEMLABMcap ₹2,910 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+6.6-1.8
EBITDA-9.5+11.7
Total Assets+4.5-7.0
Total Equity+14.5-5.8
Free Cash Flow-42.1+30.6
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.